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Aims and Background: Survivin is a recently identified protein as an inhibitor of
apoptosis, which supresses programmed cell death and regulates cell division. In this
study, we investigated the prognostic significance of both nuclear and cytoplasmic
survivin expression in non-small cell lung cancer (NSCLC) and examined the
association with clinicopathological parameters.
Methods: The study comprised 58 male patients diagnosed NSCLC with a mean age
of 57.2978.82 years; range 40–76 years. Patients underwent lobectomy (64%) or
pneumonectomy (36%) with hilar and mediastinal lymph node sampling. Paraffin
embedded tumor sections were retrieved for evaluation of nuclear and cytoplasmic
staining of survivin. Clinicopathological data, stage and survival of patients were all
determined.
Results: Cytoplasmic staining was found significantly increased in squamous cell
carcinoma (P ¼ 0:003), whereas there was no association between nuclear staining
and histopathological type (P ¼ 0:837). Also, both nuclear and cytoplasmic staining
did not show any association with tumor stage (P40:05). In univariate analysis there
was significant correlation between nuclear survivin and short survival (P ¼ 0:0002).
In multivariate survival analysis using Cox regression, only nuclear staining of
survivin was determined as an independent prognostic factor (P ¼ 0:004).
Conclusions: Localization of survivin expression might have an important regulatory
mechanism in carcinogenesis and tumor progression. Nuclear survivin expression inElsevier Ltd. All rights reserved.
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no prognostic significance.
& 2006 Elsevier Ltd. All rights reserved.Table 1 Clinical and pathological characteristics
of patients.
Factors n (%)
Age 57.2978.82 years
Smoking 24712.8 pack/years
Histopathological type
Squamous cell carcinoma 36 (62.1)
Adenocarcinoma 22 (37.9)
Stage IA 5 (8.6)
Stage IB 20 (34.5)
Stage IIB 15 (25.9)
Stage IIIA 18 (31)
Tumor diameter 4.9172.92 cmIntroduction
Lung cancer is the leading cause of cancer death all
over the world and there is no reliable and
effective diagnostic molecular markers predicting
prognosis in non-small cell lung cancer (NSCLC).1,2
Therefore, new molecular markers will allow the
development of the novel therapeutic strategies
for lung cancer.2,3 Survivin is a recently identified
protein as an inhibitor of apoptosis, which su-
presses programmed cell death and regulates cell
division.2,4 The expression of survivin is undetect-
able or found at very low levels in normal tissues,
whereas at high levels in various malignancies and
also embryonic and fetal tissues.5–7 Survivin is
expressed in the G2/M phase of the cell cycle and
at the beginning of mitosis, survivin associates with
microtubules of the mitotic spindle. Hence, the
overexpression of survivin may overcome this
apoptotic checkpoint and promote aberrant
progression of the transformed cell through
mitosis.6,8,9
High level of survivin expression in malignancies
is considered as an important indicator of poor
prognosis and associated with high tumor grade,
tumor progression and chemoresistance.7,10,11 Lung
cancer and breast cancer cells express the highest
levels of survivin and also survivin expression is
correlated with shorter survival in patients with
NSCLC.8,12,13 Survivin has both nuclear and cyto-
plasmic staining in cancer cells which involve in
regulation of mitosis and apoptosis.4 In this study,
we aimed to determine the prognostic significance
of both nuclear and cytoplasmic expression of
survivin in NSCLC and examined the association
with clinicopathological parameters.Lobectomy 37 (63.8)
Pneumonectomy 21 (36.2)
Nuclear survivin () 30 (51.7)
Nuclear survivin (+) 28 (48.3)
Cytoplasmic survivin () 2 (3.5)
Cytoplasmic survivin (+) 17 (29.3)
Cytoplasmic survivin (++) 21 (36.2)
Cytoplasmic survivin (+++) 18 (31)
Treatment modality
Chemotherapy 9 (15.5)
Radiotherapy 13 (22.4)
Chemotherapy+radiotherapy 5 (8.6)
Supportive therapy 31 (53.5)
Cisplatin-based chemotherapy regimens.Materials and methods
Patients
Archived tissue blocks from 2000–2003 were re-
trieved from the files of the Department of
Pathology in Atatu¨rk Chest Diseases and Chest
Surgery Education and Training Hospital. The study
comprised 58 male patients diagnosed NSCLC with a
mean age of 57.2978.82 years; range 40–76 years.
Patients underwent lobectomy (64%) or pneumo-nectomy (36%) with hilar and mediastinal lymph
node sampling. None of the patients received
chemotherapy or radiation therapy before surgery.
Histopathological diagnosis was carried out accord-
ing to the WHO/IASLC (1999) classification of lung
and pleural tumors.14 In our study, 36 patients were
diagnosed squamous cell carcinoma and 22 patients
were adenocarcinoma. Clinical stage was deter-
mined according to the TNM staging system
(1997).15 There were 5 patients with stage 1A, 20
patients with stage 1B, 15 patients with stage 2B,
18 patients with stage 3A. The characteristics of
patients are shown in Table 1.
Immunohistochemistry
Paraffin embedded material was available in a set
of 58 individual tumors for evaluation of nuclear
and cytoplasmic staining of survivin. The study
was carried out using a standard avidin–biotin–
peroxidase complex technique and UltraVision LP
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body against survivin Ab-2 (Neo Markers, Clo-
ne4F7). The 6-mm-thick tissue sections were
deparaffinized in xylene 2 h, washed twice in
ethanol. Survivin Ab-2 required boiling in 10mM
Citrate buffer pH 6.0 for 20min at microwave oven.
Sections were incubated with the primary antibody
solution for survivin Ab-2 at a dilution of 1:50 for
30min at room temperature. Immunoreaction was
completed with the avidin–biotin–peroxidase com-
plex kit (LabVision). After incubation with a
diaminobenside (DAB) specimens were counter-
stained with Harris haematoxylin and cover
slipped.
Survivin cytoplasmic immunoreactivity was eval-
uated semiquantitatively based on the intensity of
staining. The percentage of positive tumor cells
were evaluated in at least five areas at  400 and
scored as negative; no survivin cytoplasmic stain-
ing, 1+ (weak); 0–25% staining, 2+ (moderate);
25–50% staining and 3+ (intense); more than 50%
cytoplasmic staining. Positive survivin nuclear im-
munoreactivity was accepted as more than 25%
positive nuclei staining.Statistical analysis
Statistical analysis was performed using the SPSS
for windows release 10.0 package program. Chi-
square test was used for comparison of data
between the groups. Univariate analysis was
performed and the significance of differences in
survival between the groups was determined using
log rank test. Survival curves were computedFigure 1 Survivin immunoreactivity in neoaccording to the method of Kaplan Meier. To
evaluate the independent prognostic relevance of
nuclear and cytoplasmic staining of survivin multi-
variate analysis using Cox Regression model was
performed. A value of Po0:05 was accepted as
statistically significant.Results
Nuclear and cytoplasmic staining of survivin
in tumor tissues
Cytoplasmic survivin staining was weak in 17
(29.3%) specimens, moderate in 21 (36.2%) and
intense in 18 (31%) specimens. Also, in 2 (3.5%)
specimens cytoplasmic staining of survivin was
negative. Nuclear staining of survivin was positive
in 28 (48.3) specimens, negative in 30 (51.7%)
specimens (Figs. 1–3). There was no correlation
between nuclear and cytoplasmic expression of
survivin (P ¼ 0:984).Association with histopathological type and
tumor stage
Cytoplasmic staining was found significantly in-
creased in squamous cell carcinoma (P ¼ 0:003),
whereas there was no association between nuclear
staining and histopathological type (P ¼ 0:837).
Also, both nuclear and cytoplasmic staining did
not show any association with tumor stage
(P40:05).plastic cell nuclei of adenocarcinoma.
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Figure 2 Strong cytoplasmic immunoreactivity in an adenocarcinoma.
Figure 3 Strong cytoplasmic and nuclear immunoreactivity in basal cells of squamous cell carcinoma.
Survivin expression in non-small cell lung cancer 2223Association between survivin staining and
survival
The median survival of patients was determined as
45.176.13 months. At the end of the study 33
(56.9%) patients had died and 25 (43.1%) patients
were alive. There was significant correlation
between nuclear staining of survivin and poor
survival (P ¼ 0:0002), as shown in Table 2 and
Fig. 4. Median survival was 49.272.1 months (95%
confidience interval (CI); 45–53.3 months) in
patients having negative nuclear survivin staining,
whereas 26.778.3 months (95% CI; 10.3–43
months) in patients with positive nuclear staining.
However, there was no significant associationbetween cytoplasmic staining and survival
(P ¼ 0:4034). Multivariate survival analysis was
performed using Cox Regression model. Other
prognostic factors as age, tumor diameter, surgery
type, histopathology, tumor stage and treatment
were all determined. Only nuclear staining of
survivin was determined as an independent prog-
nostic factor (P ¼ 0:004) (Table 3).Discussion
Apoptosis is the process in which the damaged cells
are eliminated.16 Tumorigenesis involves a loss of
balance between regulators of cells proliferation
ARTICLE IN PRESS
Table 2 Prognostic significance of nuclear and cytoplasmic survivin in a univariate analysis using log rank test.
Variables 1 year 2 year 3 year Median7SE P value
Nuclear () 86.6 83.3 79.1 49.272.14 0.0002
Nuclear (+) 64.2 53.5 35.7 26.778.3
Cytoplasmic (+) 68.4 57.9 47.4 36.6718.1 0.403
Cytoplasmic (++) 76.2 71.4 56.6 4973.9
Cytoplasmic (+++) 83.3 77.8 65.8 40.274.5
Statistically significant.
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Figure 4 Survival analysis of patients with non-small cell
lung cancer based on nuclear survivin expression. There
is a significant correlation between nuclear survivin
expression and short survival (P ¼ 0:0002).
Table 3 Multivariate analysis related to survival
using Cox regression.
Variables OR 95% CI P value
Age 1 0.97–1.07 0.387
Histopathology 0.46 0.18–1.18 0.108
Tumor diameter 0.95 0.81–1.12 0.593
Surgery type 1.87 0.67–5.19 0.228
Stage I (R) — — —
Stage II 1.24 0.41–3.68 0.696
Stage III 1.85 0.65–5.25 0.247
Supportive therapy (R) — — —
Chemotherapy 0.55 0.12–2.54 0.446
Chemotherapy 2.3 0.58–9.14 0.234
+radiotherapy
Radiotherapy 1.93 0.67–5.58 0.22
Nuclear survivin 3.73 1.53–9.05 0.004
Cytoplasmic (+) (R) — — —
Cytoplasmic (++) 0.55 0.18–1.66 0.297
Cytoplasmic (+++) 0.31 0.1–0.98 0.055
Statistically significant, R: reference category.
S. Atikcan et al.2224and apoptosis. Activation of apoptosis has been
shown to be important in lung tumorigenesis and
contribute to tumor invasion and metastasis.17 The
newly identified apoptosis inbitor, survivin, has
been shown to be expressed in various human
cancers including NSCLC.2,4,17 In this study, we
aimed to investigate the clinicopathological and
prognostic significance of survivin expression in
NSCLC. We demonstrated both nuclear and cyto-
plasmic staining of survivin in tumor tissues by
immunohistochemistry. Survivin could be detected
in the majority of resected NSCLC not only as
the protein but also as mRNA. Falleni et al.2
demonstrated survivin mRNA levels higher in
squamous cell carcinomas for the first time. Also,
we found cytoplasmic survivin significantly in-
creased in squamous cell carcinoma by immunohis-
tochemistry, for the first time. However, therewas no association between nuclear survivin and
histopathology.
Survivin has dual function in apoptosis and
mitosis depending upon its cellular localization
and in a number of cancers prognostic significance
of nuclear and cytoplasmic survivin expression has
been investigated.4,9,16 In our study we found
nuclear staining of survivin as a poor prognostic
factor in NSCLC similar to the study of Lu et al.4
However, Vischioni et al.18 found nuclear localiza-
tion of survivin as a positive prognostic factor in
advanced NSCLC. This finding can be explained by
the different stages of the patients, such as in our
study we investigated NSCLC patients with early
stage, whereas Vischioni et al. analyzed patients
with advanced stage. In addition, the second
reason might be the methodogical differences,
such as the technique used to probe survivin
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nuclear staining of survivin as a poor prognostic
factor in patients with stages I and II resected
NSCLC.
The influence of nuclear and cytoplasmic survivin
on prognosis vary not only within same tumor types,
but also within different tumor types and stages.
Kennedy et al.16 found nuclear survivin as a good
prognostic factor in breast cancer, whereas Gra-
bowski et al.9 showed nuclear survivin associated
with poor survival in esophageal cancers. In NSCLC,
strong expression of survivin in nucleus might
represent increased mitotic events.4 In contrast,
cytoplasmic staining of survivin had no prognostic
relevance at all.
Survivin expression might promote both tumor
progression and resistance to chemotherapy and
irradiation.9,20 The molecular mechanisms by which
survivin inhibits apoptosis are still under investiga-
tion. It has been shown that survivin splice variants
had different subcellular localizations and func-
tions. Survivin delta EX3 is localized in nucleus,
whereas survivin 2B isoforms are found in cyto-
plasm. Although survivin delta Ex 3 preserves its
antiapoptotic potential, survivin 2B has lost its
antiapoptotic feature and also survivin 2B might act
as an antagonist of survivin.16,19,21–23 Ling et al.24
found high expression level of survivin 2B asso-
ciated with no relapse and good survival, whereas
high expression level of survivin delta Ex 3 was
determined as associated with relapse and poor
survival.
Survivin is an important predictive factor for
recurrence after curative resection in early stage
NSCLC. New strategies may be considered with
reference to survivin expression to improve treat-
ment of NSCLC after surgical resection. Further-
more, targeted chemotherapy against survivin
using monoclonal antibodies might be an approach
to treat surviving-positive tumors.17
In conclusion, localization of survivin expres-
sion might have an important regulatory mechan-
ism for its role in carcinogenesis and tumor
progression. Nuclear survivin expression in tumor
tissues might predict the prognosis in NSCLC.
Further studies comprising more patients should
be performed to investigate the prognostic sig-
nificance of nuclear and ctoplasmic survivin ex-
pression in NSCLC.References
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